
Bactiguard®

SEB Nordic Seminar

08 January 2025

Christine Lind, CEO





Bactiguard in brief

advanced technology to prevent medical device related infections

established license
partnerships with global
MedTech giants

potential in **future license partnerships**across therapeutic areas




The issue of healthcare associated infections

- 1 in 10 patients worldwide affected by healthcare associated infections (HAI)¹
- 40-60% of all HAIs caused by medical devices²
- **Up to 50%** of HAIs estimated to be **preventable**³
- Costs associated with HAIs (ie extended hospital stays and additional treatment) can be significantly reduced through proactive infection prevention strategies⁴
- WHO: Proactive infection prevention is cost-effective, offering both financial and health benefits over treatment⁵



^{2.} DiBiase, L. M. et al. (2014. Infection Control & Hospital Epidemiology, 35(2), 200–202. https://doi.org/10.1086/674847




^{3.} https://www.ecdc.europa.eu/en/healthcare-associated-infections


^{4.} ECDC. Economic evaluations of interventions to prevent healthcare-associated infections. Stockholm: ECDC; 2017.

^{5.} Global report on infection prevention and control. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.



Opportunities to prevent infections across therapeutic areas









Advanced technology to prevent medical device related infections

Reduces microbial adhesion and biofilm formation

- Biocompatible, safe and proven
- Ultra-thin noble metal coating technology
- In contact with fluids, the noble metals create a galvanic effect due to their varying electro potentials
- More than 100,000 patients in clinical trials
- Efficacy assessed in more than 40 clinical studies (various patient cohorts, regions, and therapeutic areas)
- Most recent randomized clinical studies show approximately 70% infection risk reduction ^{1, 2}







A knowledge and specialist organization

Strategic focus areas to achieve profitable and sustainable growth

License partnerships

R&D Medical Regulatory

Wound Management portfolio

Focus going forward

Advance current and develop future


Deliver competencies to enhance partnerships





Business model and partner journey

Three types of revenues – partners generating exclusivity and license revenues are communicated







BD (Becton, Dickinson and Company)

One of the largest global MedTech companies in the world

Relationship overview

- Partnership since early 90s
- ~245 million Bactiguard coated foley catheters sold by BD
- Signed **exclusive global license** (ex China) agreement late 2023 extending markets for Bactiguard coated Foley catheters
- Bactiguard provides expertise on go-to-market strategies, and regulatory matters, and training on value-add messaging

Financials

- Q1-Q3 2024 revenues: 88,9 MSEK (2023: 64,0 MSEK)
- Full-year 2023 revenues 93.1 MSEK (2022: 133.9 MSEK)







Zimmer Biomet

A **global leader** in orthopedics – comprehensive portfolio designed to maximize mobility and improve health

Relationship overview

- Partnership since 2019
- Trauma implant ZNN Bactiguard on market
 - rolled out across Europe strong recognition and demand
 - introduced in Japan
- Infection prevention a key theme at Zimmer Biomet

Financials

- Q1-Q3 2024 revenues: 24.2 MSEK (2023: 18,5 MSEK)
- Full-year 2023 revenues 21.5 MSEK (2022: 24.5 MSEK)









Wound Management by Bactiguard

Preventing infections by offering effective, biocompatible solutions to improve healing

Offering includes

- Hydrocyn aqua, an innovative wound care product enabling wound healing and preventing infection
- A wide range of surgical sutures including specialist sutures for cardiovascular operations and eye operations


Financials

- Q1-Q3 2024 revenues: 45,3 MSEK (2023: 39,9 MSEK)
- Full-year 2023 revenues 53.8 MSEK (2022: 43.7 MSEK)






Net sales grew 48% in Q3 and 23% YTD, driven by solid growth in license revenues





EBITDA grew to 9.9 MSEK in Q3 and to 9.6 MSEK YTD






Our priorities ahead

Vision: become the global standard of care for preventing medical device related infections

- Advance current partnerships with BD, Zimmer Biomet and Well Lead
- New partnerships in strategic therapeutic areas convert early-stage projects into exclusivity and license partnerships
- Continue profitable growth of Wound Management
- Build competencies within the knowledge and specialist organization further
 - corporate culture
 - specialist areas (R&D, coating, medical, commercial, and regulatory)
- Continue to deliver profitability and sustainable growth



The most promising aspect of healthcare going forward is prevention, period.

Doctor Richard Kuntz
BACTIGUARD BOARD MEMBER



